At present，there is no specific drug for the radical treatment of myasthenia gravis. The thera⁃ pies vary with different etiology and population of patients as well，with discrepancies in long⁃term and short⁃term efficacy，prognosis and safety. In order to select a safe and effective medication regimen for the patients，this paper reviews the relevant domestic and foreign studies and compares the latest guidelines of myasthenia gravis issued by the Chinese Society for Immunology and the Myasthenia Gravis Foundation of America in 2020，aiming to provide surgeons with more references for the treatment of myasthenia gravis.